Posterior Subhyaloid Precipitates: ‘KPs’ of the Posterior Segment

2021 ◽  
pp. 1-6
Author(s):  
Ashish Khalsa ◽  
Anup Kelgaonkar ◽  
Srikanta Kumar Padhy ◽  
Tushar Agarwal ◽  
Anamika Patel ◽  
...  
Keyword(s):  
Posterior Segment

Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases

2020 ◽  
Vol 36 (6) ◽  
pp. 323-341 ◽  
Author(s):  
Meltem Ezgi Durgun ◽  
Sevgi Güngör ◽  
Yıldız Özsoy
Keyword(s):  
Drug Carriers ◽  
Posterior Segment

scholarly journals In vitro dissolution testing models of ocular implants for posterior segment drug delivery

2021 ◽  
Author(s):  
Muhammad Faris Adrianto ◽  
Febri Annuryanti ◽  
Clive G. Wilson ◽  
Ravi Sheshala ◽  
Raghu Raj Singh Thakur
Keyword(s):  
Drug Release ◽  
Posterior Segment ◽  
In Vitro Dissolution ◽  
Prolonged Treatment ◽  
Term Therapy ◽  
In Vitro Test ◽  
Dissolution Testing ◽  
Vitro Test ◽  
Ocular Implants

AbstractThe delivery of drugs to the posterior segment of the eye remains a tremendously difficult task. Prolonged treatment in conventional intravitreal therapy requires injections that are administered frequently due to the rapid clearance of the drug molecules. As an alternative, intraocular implants can offer drug release for long-term therapy. However, one of the several challenges in developing intraocular implants is selecting an appropriate in vitro dissolution testing model. In order to determine the efficacy of ocular implants in drug release, multiple in vitro test models were emerging. While these in vitro models may be used to analyse drug release profiles, the findings may not predict in vivo retinal drug exposure as this is influenced by metabolic and physiological factors. This review considers various types of in vitro test methods used to test drug release of ocular implants. Importantly, it discusses the challenges and factors that must be considered in the development and testing of the implants in an in vitro setup. Graphical abstract

Electrothrombosis of carotid-cavernous fistula

1975 ◽  
Vol 42 (1) ◽  
pp. 76-85 ◽  
Author(s):  
Yoshio Hosobuchi
Keyword(s):  
Posterior Segment ◽  
Cerebral Vein ◽  
Superior Ophthalmic Vein ◽  
Carotid Cavernous Fistula ◽  
Content Type ◽  
Cavernous Fistula ◽  
Arterial Circulation ◽  
Inferior Portion ◽  
Pterygoid Plexus ◽  
Fine Print

✓ The author describes a technique for directly closing a carotid cavernous fistula with electrothrombosis while preserving the intracranial arterial circulation. Copper wires are introduced through the superior ophthalmic vein or a frontotemporal craniotomy, and thus directly into the portion of the sinus into which the fistula drains; if posterior, into the posterior segment of Parkinson's triangle, if inferior, into the pterygoid plexus, and if anterior, through the sphenoparietal sinus and/or middle cerebral vein to the anterior-inferior portion of the sinus. A direct current is applied until a thrombus is confirmed angiographically and the wires are left in place. Four patients treated by this method are presented.

scholarly journals Danish teleophthalmology platform reduces optometry referrals into the national eye care system

2021 ◽  
Vol 6 (1) ◽  
pp. e000671
Author(s):  
Danson Vasanthan Muttuvelu ◽  
Heidi Buchholt ◽  
Mads Nygaard ◽  
Marie Louise Roed Rasmussen ◽  
Dawn Sim
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort ◽  
Care Service ◽  
Posterior Segment ◽  
Eye Care ◽  
Use Of Technology ◽  
New Models ◽  
Electronic Referral ◽  
Care System

ObjectiveThe purpose of this study was to evaluate the stratification of follow-up and referral pathways after implementation of a systematic cloud-based electronic-referral teleophthalmological service for optometry-initiated ocular posterior segment disease referrals to the Danish national eye care system.Methods and AnalysisA retrospective cohort study was conducted in the period from 1 August 2018 to 31 July 2019. Patients with suspected ocular posterior segment disease reviewed by the telemedical ophthalmology service were included. The service stratified patients into the categories: no need for follow-up, follow-up by optometrist, follow-up by the telemedical service and referral to the national Danish eye care service.ResultsFrom a pool of 386 361 customers, 9938 patients were enrolled into this study. 19.5% of all patients were referred to the Danish national eye care system, while 80.5% of the patients in the telemedical service were not, in the period from 1 August 2018 to 31 July 2019. 14.4% of the optometrist referrals did not need any follow-up, while a majority of 66.1% needed some follow-up either by the optometrist themselves or within the telemedical service.ConclusionOptometrist posterior segment disease referrals can be considerably reduced with a risk stratified approach and optimal use of technology. New models can improve and streamline the healthcare system.

scholarly journals Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis

Eye ◽  
2021 ◽  
Author(s):  
Carlos Pavesio ◽  
Carsten Heinz
Keyword(s):  
Cataract Surgery ◽  
Treatment Strategies ◽  
Standard Of Care ◽  
Fluocinolone Acetonide ◽  
Posterior Segment ◽  
Recurrence Rates ◽  
Intravitreal Implant ◽  
Infectious Uveitis ◽  
Dose Corticosteroid ◽  
Fellow Eyes

Abstract Background Prevention of non-infectious uveitis of the posterior segment (NIU-PS) recurrence using 0.2 μg/day fluocinolone acetonide implant (FAi) was assessed over 3 years (NCT01694186). Outcomes for FAi-treated and fellow eyes with NIU-PS were compared, to evaluate FAi versus conventional treatment strategies. Methods Eligible subjects had >1-year recurrent NIU-PS history and either ≥2 separate recurrences requiring treatment, or corticosteroid therapy (systemic or ocular) in the 12 months preceding study entry. Bilateral disease was present and analysed in 59/87 FAi-treated participants. Recurrence rates, best-corrected visual acuity (BCVA) changes, cataract surgery, intraocular pressure (IOP) events and adjunctive medication use were compared for FAi-treated and fellow eyes. Results Over 36 months, more FAi-treated than fellow eyes remained recurrence-free (28.8% vs. 5.1%, P = 0.001; mean 1.9 vs. 4.7 recurrences, respectively, P < 0.0001). FAi-treated eyes gained +9.6 letters BCVA, versus a loss of −4.4 in fellow eyes (P < 0.0001). Systemic medications were given to 42.4% of subjects. Intra/periocular adjunctive injections were lower in FAi-treated than fellow eyes (20.3% vs. 66.1%, P < 0.0001); topical corticosteroid use was also lower in FAi-treated than fellow eyes (27.1% vs 52.5%, P = 0.0041). IOP-related events occurred at similar rates in both FAi-treated and fellow eyes, excepting IOP-lowering surgery (5.1% vs. 15.3%, respectively; P = 0.1251). Cataract surgery occurred in 72.0% of FAi-treated and 37.0% of fellow eyes. Conclusions In subjects with bilateral NIU-PS, continuous, low-dose corticosteroid with 0.2 μg/day FAi reduced recurrence and adjunctive medication requirements, and improved vision over 36 months, providing greater protection against ocular inflammation than a reactive approach using standard of care.

Sign in / Sign up

Export Citation Format

Share Document